AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18503118 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Duplex Ultrasound (CDU)
Number of subjects: 43
Study 18503118 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS)
Number of subjects: 43
Study 18503118 — intervention group
Group type: COMPARATOR
Intervention: Multislice Computed Tomography (MS-CT)
Number of subjects: 43
Study 16543739 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oral morphine (SROM)
Number of subjects: 20
Study 14651723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (180 mg)
Number of subjects: 24
Study 14651723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10757573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (DPX) 0.5 microg kg(‐1) min(‐1)
Number of subjects: 20
Study 10757573 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (DO) 2.5 microg kg(‐1) min(‐1)
Number of subjects: 20
Study 7825540 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g flaxseed/d for 4 wk
Number of subjects: 0
Study 7825540 — intervention group
Group type: COMPARATOR
Intervention: Muffins containing 25 g flaxseed
Number of subjects: 0
Study 2195577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (oral)
Number of subjects: 18
Study 2195577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 18
Study 2195577 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Wake
Number of subjects: 18
Study 2195577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine/Sleep
Number of subjects: 18
Study 2195577 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo/Sleep
Number of subjects: 18
Study 121667 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by three courses of MOPP
Number of subjects: 85
Study 121667 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 85
Study 31914811 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus bevacizumab (TT-B)
Number of subjects: 854
Study 31914811 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus bevacizumab
Number of subjects: 854
Study 31590689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with fake closed camera television (CCTV) installed after training on hand hygiene.
Number of subjects: 48
Study 31590689 — intervention group
Group type: COMPARATOR
Intervention: Control group without fake CCTV.
Number of subjects: 48
Study 28415176 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterated amplitude adjusted wavelet transform
Number of subjects: 0
Study 28415176 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26293067 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Gelofusine (GEL group)
Number of subjects: 36
Study 26293067 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyehylstarch 130/40 (HES group)
Number of subjects: 36
Study 23153900 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic hormonal fertility monitor (EHFM)
Number of subjects: 667
Study 23153900 — intervention group
Group type: COMPARATOR
Intervention: Cervical mucus monitoring (CMM)
Number of subjects: 667
Study 23153900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 667
Study 22275916 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA spirometry (incentive spirometry)
Number of subjects: 49
Study 22275916 — intervention group
Group type: COMPARATOR
Intervention: SCA control (no spirometry)
Number of subjects: 49
Study 19591335 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% CPC mouthrinse
Number of subjects: 48
Study 19591335 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse
Number of subjects: 48
Study 16581482 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Atrial Appendage (RAA) assessment
Number of subjects: 92
Study 16581482 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage (LAA) assessment
Number of subjects: 92
Study 16581482 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RAA and LAA
Number of subjects: 92
Study 12838861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and nasopharyngeal debridement and cleansing and tympanic membrane puncturing suction (Group I)
Number of subjects: 58
Study 12838861 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy or ventilation tube insertion (Group II)
Number of subjects: 58
Study 10872661 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily
Number of subjects: 0
Study 10872661 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy
Number of subjects: 0
Study 9090684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dihydroergotamine (DHE)
Number of subjects: 12
Study 9090684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8487823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 100 mg/kg/day for up to 5 days
Number of subjects: 275
Study 8487823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 150 mg/kg/day for up to 5 days
Number of subjects: 275
Study 8487823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (both dosages)
Number of subjects: 275
Study 8487823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 2962623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 15 micrograms + bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Number of subjects: 120
Study 2962623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 micrograms + bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Number of subjects: 120
Study 2962623 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Number of subjects: 120
Study 29649056 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 12
Study 29649056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27074172 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive surfactant administration (beractant 4 ml/kg)
Number of subjects: 30
Study 27074172 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (intubation, surfactant administration, early extubation)
Number of subjects: 30
Study 26671345 — intervention group
Group type: EXPERIMENTAL
Intervention: Remedial after-school lessons focusing on literacy and numeracy, 5 to 6 days a week for 3 years.
Number of subjects: 6000
Study 23751740 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional graft-distal iliac artery bypass
Number of subjects: 46
Study 23751740 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomotic stoma stenting
Number of subjects: 46
Study 23751740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fogarty catheter embolectomy plus local thrombolysis
Number of subjects: 46
Study 23751740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fogarty catheter embolectomy
Number of subjects: 46
Study 23751740 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous thrombolysis
Number of subjects: 46
Study 23751740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 46
Study 20718927 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR five-grass pollen SLIT tablets
Number of subjects: 267
Study 20718927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 17928199 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injections (5 injections per patient)
Number of subjects: 30
Study 17928199 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injections (11 injections per patient)
Number of subjects: 30
Study 17928199 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of contrast injections
Number of subjects: 30
Study 15962735 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with RF treatment (ThermaCool TC, Thermage)
Number of subjects: 84
Study 15962735 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia with RF treatment
Number of subjects: 84
Study 15962735 — intervention group
Group type: EXPERIMENTAL
Intervention: Half face with anesthesia, half face without anesthesia
Number of subjects: 84
Study 12826983 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine combined with lithium
Number of subjects: 20
Study 12826983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10384193 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade pulmonary artery flushing with alprostadil and modified Euro‐Collins solution
Number of subjects: 14
Study 10384193 — intervention group
Group type: COMPARATOR
Intervention: Antegrade flushing plus additional retrograde flushing through the pulmonary veins
Number of subjects: 14
Study 8639011 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (250 mg/mo intramuscular depot injection of Sustanon)
Number of subjects: 15
Study 8639011 — intervention group
Group type: COMPARATOR
Intervention: Control (no testosterone treatment)
Number of subjects: 15
Study 1516509 — intervention group
Group type: COMPARATOR
Intervention: IDDM patients (1569)
Number of subjects: 1569
Study 1516509 — intervention group
Group type: COMPARATOR
Intervention: IDDM males and older IDDM females
Number of subjects: 1569
Study 1516509 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic control (measured by HbA1c) and body weight (% of ideal body wt)
Number of subjects: 1569
Study 1516509 — intervention group
Group type: COMPARATOR
Intervention: IDDM volunteers for the DCCT
Number of subjects: 1569
Study 1516509 — intervention group
Group type: COMPARATOR
Intervention: Younger IDDM women
Number of subjects: 1569
Study 6148472 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 50
Study 6148472 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance plethysmography
Number of subjects: 50
Study 6148472 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m-labelled-fibrinogen scintigraphy (venoscan)
Number of subjects: 50
Study 6148472 — intervention group
Group type: COMPARATOR
Intervention: X-ray venography
Number of subjects: 50
Study 30827929 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (exendin-4)
Number of subjects: 0
Study 30827929 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 30827929 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 30827929 — intervention group
Group type: COMPARATOR
Intervention: FGF21 blockage
Number of subjects: 0
Study 29510234 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A) injection (200 units) into the gastrocnemius muscle
Number of subjects: 40
Study 26891611 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw Palmetto (SP) at 960 mg daily
Number of subjects: 21
Study 26891611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 26054177 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% hydrogen peroxide whitening strip
Number of subjects: 54
Study 26054177 — intervention group
Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 54
Study 22008269 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (0.7 g pure ethanol/kg body weight)
Number of subjects: 116
Study 22008269 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 116
Study 19707575 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk reduction
Number of subjects: 2978
Study 19707575 — intervention group
Group type: COMPARATOR
Intervention: Absolute summary statistics
Number of subjects: 2978
Study 19707575 — intervention group
Group type: COMPARATOR
Intervention: Natural frequencies
Number of subjects: 2978
Study 17260162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant myofeedback training including ergonomic counselling (Mfb)
Number of subjects: 79
Study 17260162 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic counselling alone (EC)
Number of subjects: 79
Study 15126001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo‐PGE1 (10mg in 20ml of saline, injected intravenously as a bolus once daily for 2 weeks)
Number of subjects: 27
Study 15126001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo‐PGE1
Number of subjects: 27
Study 15126001 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 11669407 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 1035 (10 mg/day)
Number of subjects: 29
Study 11669407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11579701 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 degrees angle monitor
Number of subjects: 14
Study 11579701 — intervention group
Group type: COMPARATOR
Intervention: 15 degrees angle monitor
Number of subjects: 14
Study 11579701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal lens users
Number of subjects: 14
Study 11579701 — intervention group
Group type: COMPARATOR
Intervention: Nonbifocal users
Number of subjects: 14
Study 11579701 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 14
Study 11579701 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 14
Study 7527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/5-FU chemotherapy
Number of subjects: 0
Study 7527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin/5-FU) with radiotherapy
Number of subjects: 0
Study 7527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin alone or combined with 5-FU with simultaneous radiotherapy
Number of subjects: 0
Study 7527591 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy
Number of subjects: 0
Study 7527591 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous chemoradiotherapy
Number of subjects: 0
Study 7527591 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy alone
Number of subjects: 0
Study 2691278 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 micrograms b.i.d.
Number of subjects: 25
Study 2691278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31441407 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human high mobility group box 1 (rhHMGB1) treatment group (100 μg/L rhHMGB1)
Number of subjects: 4
Study 31441407 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH pretreatment group (10 kU/L UFH + 100 μg/L rhHMGB1)
Number of subjects: 4
Study 31441407 — intervention group
Group type: COMPARATOR
Intervention: PBS control group (200 μL PBS)
Number of subjects: 4
Study 31441407 — intervention group
Group type: COMPARATOR
Intervention: UFH control group (10 kU/L UFH)
Number of subjects: 4
Study 28521796 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up supported by periodic phone calls by a nurse (intervention group) plus primary care
Number of subjects: 0
Study 28521796 — intervention group
Group type: COMPARATOR
Intervention: Routine primary care only (control group)
Number of subjects: 0
Study 25520366 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified oral rehydration solution (3 mg Zn)
Number of subjects: 0
Study 25520366 — intervention group
Group type: COMPARATOR
Intervention: Control group (without Zn-fortified ORS)
Number of subjects: 0
Study 22845710 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) pramipexole to extended-release (ER) pramipexole
Number of subjects: 228
Study 22845710 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) pramipexole
Number of subjects: 228
Study 21502384 — intervention group
Group type: EXPERIMENTAL
Intervention: QISS nonenhanced MR angiography
Number of subjects: 53
Study 21502384 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced MR angiography and digital subtraction angiography
Number of subjects: 53
Study 20175433 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey-sweetened beverage
Number of subjects: 10
Study 20175433 — intervention group
Group type: COMPARATOR
Intervention: Commercial sports drink
Number of subjects: 10
Study 20175433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16428555 — intervention group
Group type: EXPERIMENTAL
Intervention: OLEH information system
Number of subjects: 2
Study 16428555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OLEH)
Number of subjects: 2
Study 15556261 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received croissants and magdalenas enriched with sterol esters, alpha‐tocopherol and beta‐carotene
Number of subjects: 57
Study 15556261 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard croissants and muffins
Number of subjects: 57
Study 11426364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (5 g)
Number of subjects: 300
Study 11426364 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 300
Study 9438895 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 0.1 mg
Number of subjects: 519
Study 9438895 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1.0 mg
Number of subjects: 519
Study 9438895 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3.0 mg
Number of subjects: 519
Study 9438895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 8511243 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (three group educational sessions on HIV risk and protective behaviors)
Number of subjects: 0
Study 8511243 — intervention group
Group type: COMPARATOR
Intervention: Standard-only intervention
Number of subjects: 0
Study 2948754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (10 mmol/day)
Number of subjects: 11
Study 2948754 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium intake (150 mmol/day)
Number of subjects: 11
Study 2948754 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (350 mmol/day)
Number of subjects: 11
Study 2948754 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing sodium intake (from low to high)
Number of subjects: 11
Study 31203512 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic psycho-educational intervention
Number of subjects: 40
Study 31203512 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 29230568 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group
Number of subjects: 1458
Study 29230568 — intervention group
Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group
Number of subjects: 1458
Study 29230568 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (transfemoral approach)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (transfemoral approach)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (alternative approach)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (alternative approach)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (within 30 days)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (within 30 days)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (between 31 days and 2 years)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (between 31 days and 2 years)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (in-hospital vascular complications)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (in-hospital vascular complications)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (acute kidney injury)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (acute kidney injury)
Number of subjects: 1458
Study 29230568 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.9
Number of subjects: 1458
Study 26453066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion controlling glycemia at 4.5‐7.2 mmol/l (Group A)
Number of subjects: 24
Study 26453066 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin administered in three doses controlling glycemia at 7.2‐10.0 mmol/l (Group B)
Number of subjects: 24
Study 26453066 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) without disturbances in carbohydrate metabolism
Number of subjects: 24
Study 24277510 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous laser ablation (PLA)
Number of subjects: 30
Study 24277510 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency thermoablation (RFA)
Number of subjects: 30
Study 22314814 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous allergen-specific immunotherapy (SCIT)
Number of subjects: 64
Study 22314814 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment
Number of subjects: 64
Study 20389151 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand
Number of subjects: 70
Study 20389151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand plus tamsulosin 0.4 mg/day over 3 weeks
Number of subjects: 70
Study 20389151 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand (meta-analysis)
Number of subjects: 70
Study 20389151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand plus tamsulosin 0.4 mg/day over 3 weeks (meta-analysis)
Number of subjects: 70
Study 16920140 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary slow flow (CSF) patients (group I)
Number of subjects: 48
Study 15724103 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% retinaldehyde/6% glycolic acid (Diacneal)
Number of subjects: 0
Study 15724103 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 12006897 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 38